As FDA puts more emphasis on the potential of postmarket data collection to supplant premarket studies when possible, it raises the likelihood of more Medicare coverage-with-evidence development policies, CMS officials suggest.
Reimbursement considerations for products with less premarket data will also likely take more time to review and require closer collaboration with manufacturers. The FDA policy adjustment also raises questions about...